AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 SEP 19 - (NewsRx.com & NewsRx.net) --
Cambridge Antibody Technology (CAT) announced the early results from a Phase II clinical trial using CAT-152 (lerdelimumab; human anti-TGFBeta(2) monoclonal antibody) in patients undergoing surgery for glaucoma.
CAT-152 has been designed to prevent excessive postoperative scarring, which is the major reason glaucoma surgery can fail to lower intraocular pressure in the long-term.
The Phase II clinical trial studied 56 patients who underwent combined glaucoma and cataract surgery. Patients were randomized to receive either CAT-152 (36 patients) or matching placebo (20 patients) in a series of four subconjunctival injections which were given on the day of surgery (both immediately pre- and postoperatively), the day after surgery and a week after surgery.
The primary objective of the trial was to assess safety and tolerability of CAT-152 injection in this group of patients. A secondary objective was demonstration of efficacy of CAT-152.
CAT-152 was found to be safe and well tolerated in this trial with no serious drug-related adverse events and no severe injection site reactions reported. There was no evidence of increased inflammation in the anterior chamber of the eye.
Intraocular pressure (IOP) was successfully lowered by surgery in both patient groups. Three months after operation the achieved IOP was lower in patients receiving CAT-152 (mean value 14.7 mmHg) ...